QT
CLDX icon

Quantbot Technologies’s Celldex Therapeutics CLDX Stock Holding History

Quantbot Technologies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
2,935
+463
+19% +$15K ﹤0.01% 1444
2026
Q1 		$78.4K Buy
2,472
+2,326
+1,593% +$63.4K ﹤0.01% 1353
2025
Q4 		$3.96K Sell
146
-2,296
-94% -$60.5K ﹤0.01% 1627
2025
Q3 		$63.2K Buy
+2,442
New +$56.6K ﹤0.01% 1495
2024
Q4 		– Sell
-95
Closed -$3.23K – 1525
2024
Q3 		$3.23K Buy
+95
New +$3.62K ﹤0.01% 1375
2022
Q2 		– Sell
-400
Closed -$13K – 1744
2022
Q1 		$13K Sell
400
-600
-60% -$19.2K ﹤0.01% 1428
2021
Q4 		$38K Buy
1,000
+800
+400% +$34.9K ﹤0.01% 1098
2021
Q3 		$10K Sell
200
-600
-75% -$28.2K ﹤0.01% 1351
2021
Q2 		$26K Buy
+800
New +$22K ﹤0.01% 1185
2016
Q2 		– Sell
-441
Closed -$25K – 1093
2016
Q1 		$25K Buy
441
+288
+188% +$32.4K ﹤0.01% 979
2015
Q4 		$36K Buy
153
+26
+20% +$5.67K 0.01% 856
2015
Q3 		$20K Buy
+127
New +$35.9K ﹤0.01% 1023
2015
Q1 		– Sell
-27
Closed -$7K – 1089
2014
Q4 		$7K Sell
27
-631
-96% -$157K ﹤0.01% 1018
2014
Q3 		$127K Buy
+658
New +$143K 0.02% 817

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantbot Technologies's CLDX Position: Q2 2026 in Review

Quantbot Technologies increased its Celldex Therapeutics (CLDX) stake by 19% in Q2 2026, buying an estimated $15K and bringing the position to 2,935 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Quantbot Technologies first reported a position in CLDX in Q3 2014 and has held it in 14 quarters since. The position peaked at $127K in Q3 2014. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Quantbot Technologies held 2,935 shares of Celldex Therapeutics worth $109K as of Q2 2026.
  • Quantbot Technologies bought 463 Celldex Therapeutics shares in Q2 2026, an estimated $15K.
  • Celldex Therapeutics made up ﹤0.01% of Quantbot Technologies's portfolio in Q2 2026, its #1444 holding.
  • Quantbot Technologies first reported a position in Celldex Therapeutics in Q3 2014 and has held it in 14 quarters since.
  • Quantbot Technologies's Celldex Therapeutics position peaked at $127K in Q3 2014.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.